Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Berlin - Delayed Quote EUR

Astellas Pharma Inc (YPH.BE)

Compare

9.29

-0.19

(-2.01%)

At close: February 28 at 6:46:14 PM GMT+1

Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize

Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas"), and MBC BioLabs, a premier launchpad for early-stage life-science companies, today announced their collaboration on the Astellas Future Innovator Prize. The competition offers entrepreneurial scientists and emerging biotechnology start-ups one year's priority usage of MBC BioLabs' state-of-the-art Bay Area facilities and access to Astellas' research and development capabilities and business leaders.

PR Newswire 2 days ago

ALPMF

ALPMY
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As a result, IZERVAY is now approved without a limitation on duration of dosing—providing physicians and patients with greater flexibility when managing GA.

PR Newswire 16 days ago

ALPMF

ALPMY
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo

On Monday, Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase 3 EV-302 trial (also known as KEYNOTE-A39) of Padcev (enfortumab vedotin) plus Keytruda (pembrolizumab) in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Also Read: Pfizer Q4 Earnings: Revenue And EPS Beat, Seagen And COVID-19 Products Show Strength, Issues Strong FY25 Outlook The results showed a sustained overall

Benzinga 17 days ago

PFE

ALPMY
Pfizer, Astellas Cite 'Durable Benefit' in More Trial Results of Padcev Plus Keytruda in Urothelial Cancer

Pfizer (PFE) and Astellas Pharma said additional follow-up results from a phase 3 clinical trial of

PREMIUM
MT Newswires 18 days ago

PFE

ALPMY
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

NEW YORK & TOKYO, February 10, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) evaluating the efficacy and safety of PADCEV ® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus KEYTRUDA® (pembrolizumab), a PD-1 inhibitor, in patients with previously untreated locally advanced or metastatic urothe

Business Wire 18 days ago

PFE

ALPMF

ALPMY
Astellas seeks conditional approval for GA treatment in Japan

The application is supported by outcomes from the GATHER1 and GATHER2 studies.

Pharmaceutical Technology 24 days ago

ALPMY
Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan

Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for Conditional Approval of avacincaptad pegol intravitreal solution (ACP), a synthetic aptamer that inhibits the complement C5 protein, for the treatment of GA secondary to AMD. If approved, ACP has the potential to become the first and only GA treatment available in Japan.

PR Newswire 24 days ago

ALPMF

ALPMY
Astellas Makes Announcement about Management Structure

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the following changes to its management structure effective April 1, 2025.

PR Newswire 25 days ago

ALPMF

ALPMY
U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) accepted the revised supplemental New Drug Application (sNDA) for IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) on January 6, 2025, in response to the Agency's November 2024 Complete Response Letter (CRL). The application was refiled following a December 20,

PR Newswire last month

ALPMF

ALPMY
China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") today announced that China's National Medical Products Administration (NMPA) has approved PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for adult patients with locally advanced or metastatic urothelial cancer (la/mUC). The treatment combination will provide a new therapeutic option to patients with la/mUC in China and offer an alternative to platinum-containing chemotherapy, the standard of

PR Newswire last month

ALPMF

ALPMY
Astellas and Sangamo sign capsid deal for neurological diseases

Sangamo will obtain an upfront licence fee of $20m from Astellas.

Pharmaceutical Technology 2 months ago

ALPMY

SGMO
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced they have entered into a license agreement allowing Astellas to leverage Sangamo's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, which has demonstrated potent blood-brain barrier penetration and neuronal transduction in nonhuman primates. The agreement grants Astellas a worldwide exclusive license

PR Newswire 2 months ago

SGMO

ALPMF

ALPMY
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

RICHMOND, Calif. & TOKYO, December 19, 2024--Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Business Wire 2 months ago

ALPMF

ALPMY

SGMO
Astellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for Themselves

Astellas Pharma US, Inc. (TSE: 4503, Head of US Commercial: Michael Petroutsas, "Astellas") today announced the launch of Cooler Moments in partnership with Dr. Jen Ashton, a leading women's health medical expert, Founder and President of Ajenda, and former network news Chief Medical Correspondent who is board-certified in OBGYN and Obesity Medicine. Cooler Moments is an effort to inform and empower women to speak up about their moderate to severe menopausal hot flashes and night sweats, also kn

PR Newswire 2 months ago

ALPMF

ALPMY
How Astellas juggles the moving parts of cancer precision medicine development

While developing its first-in-class gastric cancer drug Vyloy, Astellas had to coordinate with another pharma giant to usher the precision med into the market.

Pharma Voice 2 months ago

ALPMY
Astellas and DOHC partner to pilot digital solution for heart failure management

The solution offers clinicians detailed patient reports, which feature important cardio acoustic biomarkers.

Medical Device Network 3 months ago

ALPMY
Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management

Astellas Pharma U.S., Inc. (President: Mike Petroutsas, "Astellas") today announced that it has entered into an agreement with Desert Oasis Healthcare (DOHC), a member of Heritage Provider Network, to pilot DIGITIVA™, a non-invasive digital health solution for the management of heart failure patients. In the next few weeks, eligible patients receiving care with DOHC will begin using DIGITIVA as a new method for managing their heart health while working in partnership with their healthcare team.

PR Newswire 3 months ago

ALPMF

ALPMY
FDA issues CRL to Astellas’ IZERVAY sNDA for geographic atrophy

The FDA's feedback centres on statistical aspects concerning the proposed labelling language.

Pharmaceutical Technology 3 months ago

ALPMY
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer

The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless founded a new startup and Novartis licensed another radiopharma drug.

BioPharma Dive 3 months ago

CYTK

NVS

ALPMY
From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies

As the industry’s marketing dollars shift, companies are targeting potential patients in unique ways.

Pharma Voice 3 months ago

ALPMY

Performance Overview

Return	YPH.BE	Nikkei 225
YTD	-0.77%	-6.87%
1-Year	-84.10%	-5.23%
3-Year	-37.74%	+40.07%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Astellas Pharma Inc (YPH.BE)

Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize

U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo

Pfizer, Astellas Cite 'Durable Benefit' in More Trial Results of Padcev Plus Keytruda in Urothelial Cancer

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Astellas seeks conditional approval for GA treatment in Japan

Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan

Astellas Makes Announcement about Management Structure

U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer

Astellas and Sangamo sign capsid deal for neurological diseases

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Astellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for Themselves

How Astellas juggles the moving parts of cancer precision medicine development

Astellas and DOHC partner to pilot digital solution for heart failure management

Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management

FDA issues CRL to Astellas’ IZERVAY sNDA for geographic atrophy

Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer

From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies

Performance Overview